{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:30:45Z","timestamp":1761823845982},"reference-count":26,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1111\/ane.12699","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T02:16:42Z","timestamp":1477016202000},"page":"54-58","source":"Crossref","is-referenced-by-count":7,"title":["JCV serology in time: 3\u00a0years of follow-up"],"prefix":"10.1155","volume":"136","author":[{"given":"M.","family":"Cambron","sequence":"first","affiliation":[{"name":"CHU Lille; Lille France"},{"name":"Universitair Ziekenhuis Brussel; Brussel Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hadhoum","sequence":"additional","affiliation":[{"name":"CHU Lille; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Duhin","sequence":"additional","affiliation":[{"name":"CHU Lille; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lacour","sequence":"additional","affiliation":[{"name":"CHU Lille; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chouraki","sequence":"additional","affiliation":[{"name":"CHU Lille; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Vermersch","sequence":"additional","affiliation":[{"name":"CHU Lille; Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2016,10,20]]},"reference":[{"key":"10.1111\/ane.12699-BIB0001|ane12699-cit-0001","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12699-BIB0002|ane12699-cit-0002","first-page":"107","article-title":"Virologic and serologic studies of progressive multifocal leukoencephalopathy","volume":"105","author":"Padgett","year":"1983","journal-title":"Prog Clin Biol Res"},{"key":"10.1111\/ane.12699-BIB0003|ane12699-cit-0003","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"issue":"Suppl 2","key":"10.1111\/ane.12699-BIB0004|ane12699-cit-0004","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/344280","article-title":"Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy","volume":"186","author":"Sabath","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1111\/ane.12699-BIB0005|ane12699-cit-0005","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1099\/vir.0.18842-0","article-title":"Seroepidemiology of the human polyomaviruses","volume":"84","author":"Stolt","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1111\/ane.12699-BIB0006|ane12699-cit-0006","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1017\/cjn.2014.32","article-title":"Anti-JC Virus Antibody Prevalence in Canadian MS Patients","volume":"41","author":"Bhan","year":"2014","journal-title":"Can J Neurol Sci"},{"key":"10.1111\/ane.12699-BIB0007|ane12699-cit-0007","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12699-BIB0008|ane12699-cit-0008","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1590\/0004-282X20130121","article-title":"Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive","volume":"71","author":"Fragoso","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1111\/ane.12699-BIB0009|ane12699-cit-0009","doi-asserted-by":"crossref","first-page":"861091","DOI":"10.1155\/2014\/861091","article-title":"Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait","volume":"2014","author":"Lamdhade","year":"2014","journal-title":"ISRN Neurol"},{"key":"10.1111\/ane.12699-BIB0010|ane12699-cit-0010","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s11481-013-9496-y","article-title":"Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab","volume":"8","author":"Dominguez-Mozo","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1111\/ane.12699-BIB0011|ane12699-cit-0011","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12699-BIB0012|ane12699-cit-0012","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ane.12699-BIB0013|ane12699-cit-0013","first-page":"2293","article-title":"Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy","volume":"259","author":"Outteryck","year":"2012","journal-title":"J\u00a0Neurol"},{"key":"10.1111\/ane.12699-BIB0014|ane12699-cit-0014","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/ane.12475","article-title":"Anti-JC virus seroprevalence in a Finnish MS cohort","volume":"133","author":"Kolasa","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12699-BIB0015|ane12699-cit-0015","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12699-BIB0016|ane12699-cit-0016","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12699-BIB0017|ane12699-cit-0017","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/ene.12988","article-title":"High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"Vennegoor","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12699-BIB0018|ane12699-cit-0018","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/1352458513475489","article-title":"An assay to quantify species-specific anti-JC virus antibody levels in MS patients","volume":"19","author":"Warnke","year":"2013","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12699-BIB0019|ane12699-cit-0019","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.msard.2014.01.005","article-title":"Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice","volume":"3","author":"Carruthers","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1111\/ane.12699-BIB0020|ane12699-cit-0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458513495582","article-title":"Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients","volume":"20","author":"Rossum","year":"2014","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12699-BIB0021|ane12699-cit-0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","article-title":"Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Borchardt","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1111\/ane.12699-BIB0022|ane12699-cit-0022","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12699-BIB0023|ane12699-cit-0023","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1111\/ane.12699-BIB0024|ane12699-cit-0024","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/1352458515607651","article-title":"PML risk stratification using anti-JCV antibody index and L-selectin","volume":"22","author":"Schwab","year":"2016","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12699-BIB0025|ane12699-cit-0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24345","article-title":"Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab","volume":"77","author":"Villar","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12699-BIB0026|ane12699-cit-0026","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann Neurol"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12699","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12699\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:50:00Z","timestamp":1671540600000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,20]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12699","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10,20]]}}}